Fundraising FoxPhosplatin Therapeutics
New York, US · Delaware corporation
Find your way into Phosplatin Therapeutics
Sign up to see every warm intro you have to Phosplatin Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Phosplatin Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
FB
Frances BonhamNamed on SEC filing
RF
Robert FallonNamed on SEC filing
MP
Matthew PriceNamed on SEC filing
PE
Peter EspigNamed on SEC filing
JC
John CaouetteNamed on SEC filing
RL
Rosita LeongNamed on SEC filing
JP
John PorterNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$72.3M disclosed across 3 rounds · 2018–2021
▶$37.3MraisedDec 2021 · 41 investors · PharmaceuticalsRule 506(b)
▶$37.3MraisedDec 2021 · 41 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Rosita LeongDirector
- Robert FallonExecutive Officer, Director
- John CaouetteDirector
- Peter EspigDirector
- Frances BonhamExecutive Officer
- Neil SunderlandDirector
- Charles StuckeyDirector
- Elizabeth TallettDirector
- Matthew PriceDirector
- Offering amount
- $37.3M
- Amount sold
- $37.3M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.4MraisedAug 2020 · 40 investors · PharmaceuticalsRule 506(b)
▶$18.4MraisedAug 2020 · 40 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John PorterDirector
- Frances BonhamExecutive Officer
- John CaouetteDirector
- Fallon RobertExecutive Officer, Director
- Matthew PriceExecutive Officer, Director
- Rosita LeongDirector
- Neil SunderlandDirector
- Peter EspigDirector
- Offering amount
- $18.4M
- Amount sold
- $18.4M
- Minimum investment
- $50K
- First sale
- Jul 2020
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$16.6MraisedNov 2018 · 48 investors · PharmaceuticalsRule 506(b)
▶$16.6MraisedNov 2018 · 48 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Frances BonhamExecutive Officer
- Robert FallonExecutive Officer, Director
- Matthew PriceExecutive Officer, Director
- Peter EspigDirector
- John CaouetteDirector
- Rosita LeongDirector
- John PorterDirector
- Offering amount
- $16.6M
- Amount sold
- $16.6M
- First sale
- Oct 2018
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Phosplatin Therapeutics raised?
- Phosplatin Therapeutics has disclosed $72.3M raised across 3 rounds.
- Where is Phosplatin Therapeutics headquartered?
- Phosplatin Therapeutics is headquartered in New York, US.